| Expression pattern: |
DS |
| Associated gene: |
P2Y12 receptor |
| Associated microRNA: |
miR-126 |
| Biological function: |
Associated with ticagrelor antiplatelet responsiveness and predicts adverse ischemic events in ticagrelor-treated ACS patients. |
| Molecular mechanism: |
Not investigated; bioinformatics prediction suggested potential binding sites on miR-126 and a hypothesized effect on P2Y12 receptor expression. |
| Biological pathway or process: |
drug response (other); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Cohort Study; Survival Analysis; ROC Analysis |
| Clinical significance: |
High circFAM13B expression (> 1.05) predicts a higher risk of adverse ischemic events and improves prediction when combined with clinical risk factors. |
| Description: |
In ticagrelor-treated ACS patients, platelet-derived circFAM13B level is associated with antiplatelet responsiveness (HTPR) and independently predicts adverse ischemic events during follow-up. A miR-126/P2Y12-related mechanism is proposed only by bioinformatics prediction and hypothesis, without experimental validation. |
| Confidence score: |
0.4992 |